Assessment of Airway Obstruction in Infants With Lower Respiratory Infections

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

59 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-12-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate how two different aerosol medications may improve airway function in infants with respiratory illness. We are using two different medications and comparing the difference in lung function after each medication. We will also be taking a nasal wash sample for VEGF. We will be using this in comparing how infants respond to the aerosol medications as well. We hope to help standardize medications used for infants with bronchiolitis and RSV.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inhaled Albuterol Sulfate For Acute Wheezing Due To Obstructive Airways Disease In Children

NCT00144846

Asthma

COMPLETED PHASE3

Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants

NCT01748045

Bronchopulmonary Dysplasia

TERMINATED PHASE2/PHASE3

A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact

NCT03969992

Respiratory Distress Syndrome in Premature Infant

COMPLETED PHASE2

Nasal High Frequency Ventilation in Preterm Infants: A Pilot Study

NCT00296231

Infant Respiratory Distress Syndrome Respiratory Insufficiency Apnea of Prematurity

COMPLETED PHASE1

Status Asthmaticus on the PICU; Intravenous Salbutamol

NCT03493503

Childhood Asthma With Status Asthmaticus

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We hypothesize that VEGF production is higher in children with RSV infection than in children with other viral infections and normal controls. In addition, the degree of VEGF production is related to severity of airway obstruction. We also hypothesize that infants with higher VEGF levels are more likely to improve lung function following racemic epinephrine than albuterol.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Bronchiolitis Respiratory Syncytial Virus Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Infants with viral lower respiratory infections

Infants between the ages of 2-24 month, with viral lower respiratory infection defined as first episode of wheezing and shortness of breath preceded by an upper respiratory tract infection, including hospitalized infants

Group Type OTHER

Inhaled primatene will be given as a breathing treatment

Intervention Type DRUG

While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.

Nasal Washing

Intervention Type OTHER

1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Healthy Control

Healthy infants between the ages of 2-24 month

Group Type OTHER

Inhaled primatene will be given as a breathing treatment

Intervention Type DRUG

While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.

Nasal Washing

Intervention Type OTHER

1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Bronchiolitis-Nasal wash only

Infants 2 months to 24 months who were diagnosed with bronchiolitis received nasal wash only

Group Type OTHER

Nasal Washing

Intervention Type OTHER

1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inhaled primatene will be given as a breathing treatment

While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.

Intervention Type DRUG

Nasal Washing

1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

epinephrine 0.5ml of the 2.25% concentration

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Group 1 Infants between 2 and 24 months that are healthy
* Group 2 Infants between 2 and 24 months that have RSV or bronchiolitis and defined as the first episode of wheezing